✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

Sichuan Kelun Pharmaceutical Co Ltd

Common Name
Sichuan Kelun Pharmaceutical
Country
China (Mainland)
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
21,864
Ticker
002422
Exchange
SHENZHEN STOCK EXCHANGE
Description
Sichuan Kelun Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, specializing in the research, development, manufacturing, and distribution of a wide array of medical and h...

Sichuan Kelun Pharmaceutical's GHG Emissions Data Preview

In 2024, Sichuan Kelun Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Sichuan Kelun Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)202420232022
2021 - 2017
Total Scope 1
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
0000000
Total Scope 2
Unspecified Calculation Method
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
b
0000000
Total Scope 3
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
0000000
Limited Data Preview
You are viewing a limited preview of Sichuan Kelun Pharmaceutical’s GHG emissions dataset. The full dataset, available for download, includes Scope 1, 2, and 3 emissions with detailed category-level breakdowns, historical coverage back to 2021, and revenue-based intensity metrics for each scope.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=002422&reporting_period=2024"

Verified Sources Behind Sichuan Kelun Pharmaceutical’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Sichuan Kelun Pharmaceutical’s data sources below and access millions more through our Disclosure Search.

a. Sichuan Kelun Pharmaceutical's ESG Report 2024
b. Sichuan Kelun Pharmaceutical's ESG Report 2022

Insights into Sichuan Kelun Pharmaceutical's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Sichuan Kelun Pharmaceutical amounted to 2,845,549.25 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Sichuan Kelun Pharmaceutical increased by 7%, suggesting that the company faced challenges in reducing its emissions from its core operations.a

Sichuan Kelun Pharmaceutical's Scope 1 Emissions Over Time

20212022202320240600 k1.2 M1.8 M2.4 MtCO2e+3%+3%+8%
  • Total Scope 1
  • Year-over-Year Change

What are Sichuan Kelun Pharmaceutical's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Sichuan Kelun Pharmaceutical were 2,361,763.17 metric tons of CO₂ equivalent (tCO₂e).a

Has Sichuan Kelun Pharmaceutical reduced its Scope 1 emissions over time?

Since 2021, Sichuan Kelun Pharmaceutical's Scope 1 emissions have increased by 14.22%, reflecting a rising long-term trend in Scope 1 emissions over time.ab

Compared to the previous year (2023), Sichuan Kelun Pharmaceutical's Scope 1 emissions increased by 7.81%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a

What are Sichuan Kelun Pharmaceutical's Scope 2 emissions?

In 2024, Sichuan Kelun Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 483,786.08 tCO₂e without specifying the calculation method.a

Has Sichuan Kelun Pharmaceutical reduced its Scope 2 emissions over time?

Since 2021, Sichuan Kelun Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 92.28%, reflecting a rising long-term trend in Scope 2 emissions over time.ab

Compared to the previous year (2023), Sichuan Kelun Pharmaceutical's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Sichuan Kelun Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.a

What methodology does Sichuan Kelun Pharmaceutical use for Scope 2 reporting?

In 2024, Sichuan Kelun Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.a

Sichuan Kelun Pharmaceutical's Scope 2 Emissions Over Time

20212022202320240150 k300 k450 k600 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Sichuan Kelun Pharmaceutical’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Sichuan Kelun Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 2,361,763.17 tCO₂e and total revenues of USD 2,989 millions. This translates into an emissions intensity of 790.21 tCO₂e per millions USD.a

Sichuan Kelun Pharmaceutical's Scope 1 Emissions Intensity Compared to Peers

501,00020,000500,00010,000,000Scope 1 Emissions (tCO2e)201001,0005,00050,000Revenues (Millions of USD)CACWZADCJCTSimcere Pharmaceutical GroupYear: 2023Scope 1: 4,997 tCO2eRevenue: $M 1,017Scope 1 Intensity: 4.91 tCO2e/$MCCCR Double-CraneYear: 2024Scope 1: 58,155 tCO2eRevenue: $M 1,536Scope 1 Intensity: 37.86 tCO2e/$MHangzhou Tigermed ConsultingYear: 2024Scope 1: 210 tCO2eRevenue: $M 905Scope 1 Intensity: 0.23 tCO2e/$MMicroport ScientificYear: 2023Scope 1: 3,168 tCO2eRevenue: $M 7,404Scope 1 Intensity: 0.43 tCO2e/$MAAAscentage PharmaYear: 2023Scope 1: 2,081 tCO2eRevenue: $M 34Scope 1 Intensity: 61.05 tCO2e/$MShanghai Junshi BiosciencesYear: 2024Scope 1: 5,308 tCO2eRevenue: $M 267Scope 1 Intensity: 19.88 tCO2e/$MHumanwell Healthcare GroupYear: 2024Scope 1: 19,500 tCO2eRevenue: $M 3,485Scope 1 Intensity: 5.60 tCO2e/$MLivzon Pharmaceutical GroupYear: 2024Scope 1: 194,441 tCO2eRevenue: $M 1,619Scope 1 Intensity: 120.13 tCO2e/$MCCChangchun High-TechYear: 2023Scope 1: 61,590 tCO2eRevenue: $M 2,050Scope 1 Intensity: 30.05 tCO2e/$MWWWinner MedicalYear: 2024Scope 1: 32,223 tCO2eRevenue: $M 1,230Scope 1 Intensity: 26.19 tCO2e/$MJoincareYear: 2024Scope 1: 197,854 tCO2eRevenue: $M 2,140Scope 1 Intensity: 92.45 tCO2e/$MBioKangtaiYear: 2023Scope 1: 15,952 tCO2eRevenue: $M 489Scope 1 Intensity: 32.60 tCO2e/$MZZZhangzhou Pientzehuang PharmaceuticalYear: 2023Scope 1: 2,301 tCO2eRevenue: $M 1,415Scope 1 Intensity: 1.63 tCO2e/$MAAApeloa PharmaceuticalYear: 2024Scope 1: 10,400 tCO2eRevenue: $M 1,647Scope 1 Intensity: 6.31 tCO2e/$MWeigao GroupYear: 2024Scope 1: 3,096 tCO2eRevenue: $M 1,952Scope 1 Intensity: 1.59 tCO2e/$MZhifeiYear: 2024Scope 1: 13,576 tCO2eRevenue: $M 3,572Scope 1 Intensity: 3.80 tCO2e/$MDDDong-E-E-JiaoYear: 2023Scope 1: 15,659 tCO2eRevenue: $M 663Scope 1 Intensity: 23.60 tCO2e/$MTasly Pharmaceutical GroupYear: 2024Scope 1: 37,370 tCO2eRevenue: $M 1,164Scope 1 Intensity: 32.09 tCO2e/$M3SBioYear: 2024Scope 1: 13,304 tCO2eRevenue: $M 1,364Scope 1 Intensity: 9.75 tCO2e/$MCCCSPC Pharmaceutical GroupYear: 2024Scope 1: 474,567 tCO2eRevenue: $M 4,327Scope 1 Intensity: 109.67 tCO2e/$MJJJointown Pharmaceutical GroupYear: 2024Scope 1: 36,924 tCO2eRevenue: $M 20,801Scope 1 Intensity: 1.78 tCO2e/$MCCChina National MedicinesYear: 2024Scope 1: 907 tCO2eRevenue: $M 6,934Scope 1 Intensity: 0.13 tCO2e/$MTTTong Ren Tang TechnologiesYear: 2024Scope 1: 30,000 tCO2eRevenue: $M 1,086Scope 1 Intensity: 27.62 tCO2e/$MWuXi Biologics (Cayman)Year: 2024Scope 1: 38,346 tCO2eRevenue: $M 2,779Scope 1 Intensity: 13.80 tCO2e/$MSichuan Kelun PharmaceuticalYear: 2024Scope 1: 2,361,763 tCO2eRevenue: $M 2,989Scope 1 Intensity: 790.21 tCO2e/$M

How does Sichuan Kelun Pharmaceutical's GHG emissions intensity compare to its peers?

In 2024, Sichuan Kelun Pharmaceutical reported a Scope 1 emissions intensity of 790.21 tCO₂e per millions USD. Compared to the peer group median of 16.84, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a

Where does Sichuan Kelun Pharmaceutical rank on GHG emissions intensity within its industry?

In 2024, Sichuan Kelun Pharmaceutical ranked 25 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

This places Sichuan Kelun Pharmaceutical among the least efficient performers, with one of the highest emissions intensities in its sector.a

Want Full Access to Sichuan Kelun Pharmaceutical's GHG Emissions Dataset?
Start 30-Day Free Trial